Dirk Sauer
Directeur/Membre du Conseil chez Iconic Therapeutics, Inc.
Fortune : 8 066 $ au 31/05/2024
Postes actifs de Dirk Sauer
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Directeur/Membre du Conseil | 20/04/2021 | - |
Historique de carrière de Dirk Sauer
Anciens postes connus de Dirk Sauer
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/10/2011 | 01/03/2021 |
| CALCIMEDICA, INC. | Directeur/Membre du Conseil | 13/04/2022 | - |
| Independent Dir/Board Member | 13/04/2022 | - |
Formation de Dirk Sauer
| University of Münster | Undergraduate Degree |
| Philipps University of Marburg | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Allemagne | 3 |
| Suisse | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA. | Health Technology |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
- Bourse
- Insiders
- Dirk Sauer
- Expérience
